Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.

Summary

In the TANDEM phase 3 trial, the obicetrapib–ezetimibe fixed-dose combination reduced LDL cholesterol by 48.6% versus placebo and provided additional reductions versus either monotherapy over 84 days, with similar adverse event rates across active arms. Obicetrapib monotherapy reduced LDL-C by 31.9% versus placebo.

Key Findings

• At day 84, the fixed-dose combination reduced LDL-C versus placebo by −48.6% (95% CI −58.3 to −38.9).
• The fixed-dose combination outperformed ezetimibe (−27.9%) and obicetrapib (−16.8%) monotherapies for LDL-C lowering.
• Obicetrapib monotherapy reduced LDL-C by 31.9% versus placebo.
• Adverse event and serious adverse event rates were similar across active treatment groups and placebo.

Clinical Implications

Clinicians may consider the obicetrapib–ezetimibe fixed-dose combination to intensify LDL-C lowering when statins alone are insufficient or not tolerated, while awaiting cardiovascular outcomes data.

Limitations

• Short follow-up (84 days) and reliance on surrogate LDL-C endpoints without cardiovascular outcomes
• Industry-funded study; moderate sample size

Future Directions

Outcome trials assessing ASCVD events with obicetrapib–ezetimibe FDC, head-to-head comparisons against PCSK9 inhibitors or inclisiran, and adherence/economic evaluations.